Common Myths About Macular Degeneration
What AMD Actually Does to Your Vision
Understanding how AMD affects the eye is the first step toward managing it well. Several widespread beliefs about AMD's impact on vision are incorrect, and those misunderstandings can affect how seriously patients take the condition.
AMD damages the macula, the central part of the retina responsible for sharp, detailed vision. It does not destroy peripheral vision, which is the side vision that surrounds your central field of view. Even in advanced AMD affecting both eyes, most patients retain enough peripheral vision to move around their environment, detect objects, and carry out basic daily activities.
This does not mean AMD is minor. The central vision lost to AMD is the vision used for reading, driving, recognizing faces, and seeing fine detail. That loss is significant, which is why early detection matters so much.
AMD can begin developing in people in their 50s. While the risk of AMD rises with age, it is not limited to those in their 70s or 80s. Genetics, smoking history, cardiovascular disease, and long-term UV exposure can all accelerate the timeline. Adults over 50 with any of these risk factors should discuss screening with their eye care provider rather than waiting for symptoms to appear.
AMD affects both eyes in most patients, though it often progresses at different speeds in each eye. If AMD is present in one eye, the risk of developing it in the other eye is meaningfully elevated. For this reason, monitoring both eyes is a standard part of AMD care, even when one eye appears to be unaffected.
The Truth About AMD Treatment
Treatment options for AMD have expanded significantly, yet many patients still believe little can be done. These misconceptions can lead people to give up on care that could genuinely preserve their vision.
Anti-VEGF injections (medications that block a protein called vascular endothelial growth factor, which drives abnormal blood vessel growth) have transformed outcomes for wet AMD. Many patients who receive consistent treatment stabilize their vision, and some experience meaningful improvement. Missing injection appointments can allow vision loss to return, so staying on a regular treatment schedule is essential.
Dry AMD is no longer a condition without treatment options. AREDS2 supplements, a specific formula of vitamins and minerals, reduce the risk of progression from intermediate AMD to late AMD. Two injectable treatments have also been approved for geographic atrophy, which is the most advanced form of dry AMD, and they work by slowing the growth of retinal damage. These treatments do not restore lost vision, but they can meaningfully slow disease progression.
AMD is a disease of the retina, not a focusing problem. No glasses prescription can repair or compensate for retinal damage. Standard eyeglasses correct refractive errors such as nearsightedness, farsightedness, or astigmatism. Low vision aids, including handheld magnifiers, video magnifiers, and tinted filters, can help patients make better use of their remaining vision, but they do not treat the underlying disease.
AMD Prevention and Early Detection
Some patients believe AMD is entirely beyond their control, while others believe certain supplements will prevent it from ever developing. Both ideas miss the mark. Understanding what actually works, and what does not, helps you focus on steps that matter.
While there is no way to eliminate AMD risk entirely, certain choices meaningfully lower it. Quitting smoking is considered the single most impactful modifiable step a person can take. Other protective habits include eating a diet rich in leafy green vegetables and fish, managing blood pressure and cholesterol, maintaining a healthy weight, and wearing UV-blocking sunglasses outdoors. Early AMD detected through regular screening also allows for proactive monitoring before vision loss occurs.
Early AMD often causes no noticeable changes in vision at all. Many patients do not become aware of any symptoms until the disease has progressed to an intermediate or late stage, when vision loss is already underway. Waiting for symptoms before seeking an eye exam is one of the most common and potentially harmful misconceptions about this disease. A dilated eye exam, in which drops widen the pupil so the doctor can view the retina clearly, can detect AMD before any symptoms develop.
AREDS2 supplements are proven to slow the progression of existing AMD, specifically the transition from intermediate to advanced disease. They do not prevent AMD from developing in someone who does not already have it, and they have not been shown to slow the earliest stage of AMD. These supplements are recommended for patients who already have intermediate AMD or advanced AMD in one eye, not as a general prevention measure for the broader population.
Screen Time, Lifestyle, and AMD
Patients frequently change their daily habits out of concern that ordinary activities are worsening their AMD. Most of these concerns are not supported by clinical evidence, and avoiding activities you enjoy will not protect your vision.
There is no scientific evidence that blue light from digital devices such as computers, tablets, or smartphones causes or accelerates AMD. Concerns about blue light and the retina have emerged largely from laboratory studies using light intensities far greater than anything a screen produces. Patients with AMD do not need to avoid screens. Using accessibility features such as larger text, high-contrast display settings, and screen magnification can make devices easier and more comfortable to use.
Blue-light-filtering glasses are widely marketed, but clinical evidence does not support their use as protection against AMD. Large studies have not found a meaningful benefit from these lenses in reducing AMD incidence or slowing its progression. Tinted lenses prescribed by a low vision specialist serve a different and legitimate purpose, reducing glare and improving contrast for people with existing vision loss, but that is not the same as AMD protection.
Using your eyes for reading, needlework, crafts, or any other close activity does not accelerate AMD or cause additional damage to the retina. The macular degeneration that occurs in AMD is driven by biological and genetic disease processes, not by how often or how intensely you use your eyes. Avoiding activities you enjoy will not slow AMD, and there is no reason to give up reading or other close work because of this disease.
Genetics, Risk Factors, and AMD
AMD risk is shaped by a combination of genetic and lifestyle factors. Misconceptions about the role of family history and genetic testing can lead people to either overestimate or underestimate their personal risk.
Genetics play a substantial role in AMD risk, with a large share of disease variability linked to inherited factors. However, many people who develop AMD have no family history of the condition. Smoking, cardiovascular disease, poor diet, and UV exposure also contribute meaningfully to risk. Your personal risk is shaped by both genetic makeup and lifestyle, not by family history alone.
Routine genetic testing for AMD is not currently recommended as a standard part of eye care practice. Testing has not been shown to improve outcomes or change clinical treatment recommendations. AREDS2 supplements, for example, have been shown to benefit patients regardless of genetic profile. Carrying gene variants associated with higher AMD risk increases your statistical odds but does not guarantee you will develop the disease, and those without high-risk variants can still develop AMD.
Age is the strongest risk factor for AMD, but AMD is a disease, not an inevitable outcome of aging. Most people, even those in their 80s, do not develop AMD. Treating AMD as an expected part of growing older can discourage people from pursuing screening and treatment, both of which can make a meaningful difference in long-term outcomes.
Frequently Asked Questions
These questions address common points of confusion that patients raise when learning about AMD for the first time.
AMD targets the exact part of your vision you rely on most. Reading a book, recognizing a face, reading a street sign, watching television, and performing most detailed tasks all depend on central vision. Losing that ability changes everyday life in profound ways, even when side vision remains. The severity of that functional impact is why early detection and treatment are so important, because once central vision is lost, it cannot be fully restored.
No. AREDS2 is a specific, clinically studied formula containing vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper, in precise amounts shown to reduce AMD progression risk. General multivitamins and over-the-counter eye vitamins are not formulated to the same standard and have not been shown to provide the same benefit. Only patients with intermediate or late-stage AMD in one eye are recommended to take AREDS2, so it is important to ask your provider whether this formula is appropriate for your specific stage.
No currently available treatment reverses AMD damage. Anti-VEGF injections for wet AMD can stabilize vision and, in some cases, produce modest improvement, but they do not restore the retina to its original state. For dry AMD, available treatments slow the progression of damage rather than undo it. Research into gene therapy and stem cell-based approaches is ongoing, but these remain investigational as of 2026.
Yes, and this is especially true for AMD. Early AMD causes no symptoms that you would notice on your own. By the time distortion or blurring becomes apparent, the disease has typically already progressed beyond the earliest stage. A dilated eye exam allows the provider to examine the retina directly and detect changes that are invisible without that view. The earlier AMD is found, the more options exist to protect your remaining vision.
No. A family history of AMD increases your risk but is not a requirement for developing the disease. Many AMD patients have no affected relatives. Adults over 50, particularly those with a history of smoking, cardiovascular disease, or significant sun exposure, should discuss AMD screening with their provider regardless of family history. Waiting for a family connection before seeking care can allow the disease to progress undetected.
Yes. If you notice sudden changes in your central vision, including new blurriness, distortion that makes straight lines appear wavy or bent, or a dark or blank spot in the center of what you see, contact your eye care provider promptly. These can be signs of wet AMD developing or progressing, and faster evaluation leads to faster treatment. Do not wait for your next scheduled exam if any of these changes appear.
We Are Here to Help You Understand Your Eye Health
Accurate information is one of the most powerful tools for protecting your vision. Our team is committed to providing thorough, honest guidance so every patient understands their AMD risk, their options, and what to expect at every stage of care. We encourage you to schedule a dilated eye exam and bring any questions or concerns you have, no matter how small they may seem.
The practice is impeccable. Drs medical skills gave me extra years of vision when I had no hope. Staff are professional and kind.
Vantura Henderson
El Dr. Fernandes ha sido completamente honesto y muy servicial conmigo desde el principio. La recepcionista y todo el personal de apoyo son muy amables y siempre hacen que el paciente se sienta cómodo.
bruce hulman
Clínica fantástica. El Dr. Fernández resuelve rápidamente los problemas que ve en el momento y recomienda soluciones para seguir adelante. Siempre hay disponibilidad para emergencias, etc.
Shyam Srinivasan
El Dr. Fernández y su equipo son profesionales, atentos y siempre están pendientes de los pacientes. Tratan a cada paciente como a una persona digna de atención personal y dedicación completa.
SS
This place is great the doctor really takes his time with patients. He explains treatments and procedures well, staff are friendly, and they even offer a breakfast bar for everyone.
SLK Production